PFS Stock Overview

Provident Financial Services, Inc. (NYSE:PFS ) Q4 2024 Results Conference Call January 29, 2025 10:00 AM ET Company Participants Adriano Duarte - Head & Investor Relations Officer Tony Labozzetta - President and Chief Executive Officer Tom Lyons - Senior Executive Vice President and Chief Financial Officer Conference Call Participants Mark Fitzgibbon - Piper Sandler Billy Young - RBC Capital Markets Tim Switzer - KBW Feddie Strickland - Hovde Group Manuel Navas - D.A. Davidson Operator Good morning, and welcome everyone to the Provident Financial Services, Inc. Fourth Quarter Earnings Conference Call.

The headline numbers for Provident Financial (PFS) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Provident Financial (PFS) came out with quarterly earnings of $0.37 per share, missing the Zacks Consensus Estimate of $0.50 per share. This compares to earnings of $0.36 per share a year ago.

ISELIN, N.J., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Provident Financial Services, Inc. (NYSE:PFS) (the “Company”) reported net income of $48.5 million, or $0.37 per basic and diluted share for the three months ended December 31, 2024, compared to $46.4 million, or $0.36 per basic and diluted share, for the three months ended September 30, 2024 and $27.3 million, or $0.36 per basic and diluted share, for the three months ended December 31, 2023. For the year ended December 31, 2024, net income totaled $115.5 million, or $1.05 per basic and diluted share, compared to $128.4 million, or $1.72 per basic and $1.71 per diluted share, for the year ended December 31, 2023.

Funding is provided through the FHBNY's Small Business Recovery Grant Program Funding is provided through the FHBNY's Small Business Recovery Grant Program

Basel, 13 December 2024– Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency has approved Vabysmo® (faricimab) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of neovascular or ‘wet' age-related macular degeneration (nAMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). Together, these three conditions affect more than nine million people in the European Union (EU) and can have a devastating impact – physically, emotionally, and economically – on those affected, their families and caregivers.1-5

AbraSilver's updated PFS for Diablillos shows a 50% increase in after-tax NPV-5, mainly driven by favorable fiscal regime changes. However, the update seems to have been misunderstood by the market. The RIGI program is a boon for Diablillos economics and helps establish a timeline with a fixed deadline, with Diablillos to potentially pour first silver by 2029. Diablillos' low full-cycle cost positions it as a top-tier silver project with substantial upside potential, despite inherent risks.

- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts - Recommended Phase 2 dose (RP2D) of inupadenant 80mg + carboplatin/pemetrexed demonstrated 73.3% ORR, with 64.6% of patients achieving landmark 6-month PFS - Inupadenant + carboplatin/pemetrexed safety profile was manageable and tolerable, with no dose-dependent toxicity observed - Inupadenant deprioritized to focus resources on other programs

ENDEAVOUR ANNOUNCES POSITIVE PFS RESULTS FOR ASSAFOU PROJECT IN CÔTE D'IVOIRE $1,526m NPV (5%) and IRR of 28% at $2,000/oz • 329kozpa at AISC of $892/oz over first 10 years HIGHLIGHTS: PFS confirms Assafou's potential to become a tier 1 asset for Endeavour PFS highlights 329kozpa production at AISC of $892/oz over first 10 years: 15-year mine life based on maiden reserve of 4.1Moz Robust project economics with after-tax NPV ( 5%) of $1,526m and IRR of 28%, at a $2,000/oz gold price Initial capital of $734m based on a 5Mtpa design nameplate capacity with a similar processing plant configuration as the nearby Lafigué mine 90% resource to reserve conversion with defined maiden reserves of 72.8Mt at 1.76g/t for 4.1Moz Indicated resources of 73.6Mt at 1.95g/t for 4.6Moz based on a drilling cutoff in October 2023, with over 70,000 metres of drilling completed subsequently Further resource expansion and definition at Assafou, and satellite deposits in close proximity to Assafou, is expected to be incorporated into the DFS Given the high-quality project and attractive economics, the DFS will now commence with completion expected between late 2025 and early 2026   Abidjan , 11 December 2024 – Endeavour Mining plc (LSE:EDV, TSX:EDV, OTCQX:EDVMF) (“Endeavour”, the “Group” or the “Company”) is pleased to announce that it has recently completed a positive Pre-Feasibility Study (“PFS”) for the Assafou-Dibibango (“Assafou”) project on the Tanda-Iguela property in Côte d'Ivoire. The PFS results meet Endeavour's strategic targets and confirm Assafou's potential to be a tier 1 asset, which justifies advancing the project to the Definitive Feasibility Study (“DFS”) stage.